← FDA DRUG APPROVALS

FDA ANDA · ANDA209133

ERTAPENEM

Sponsor: EUGIA PHARMA

APPLICATION
ANDA209133
TYPE
ANDA
ORIGINAL APPROVAL
2018-06-25
LATEST ACTION
2024-06-13
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INTRAMUSCULAR, INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ERTAPENEM SODIUMPrescription
ERTAPENEM SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INTRAMUSCULAR, INTRAVENOUS

Approval history

2024-06-13Labeling · Supplement 15 · standardAP
2023-01-27Labeling · Supplement 8 · standardAP
2022-01-27Labeling · Supplement 5 · standardAP
2020-06-09Labeling · Supplement 3 · standardAP
2019-08-30Labeling · Supplement 1 · standardAP
2018-06-25UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →